Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
SENORES •NSE
Senores Pharmaceuticals
₹1,402.600.00 (0.00%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
Performance
Today’s low
1,391.70
Today’s high
1,441.90
52 week low
662.45
52 week high
1,599.00
Open price
1,423.60
Previous close
1,402.60
Live volume
3,25,710
Lower circuit
1,122.10
Upper circuit
1,683.10
Fundamentals
Market Cap
₹6,470Cr
ROE
12.36%
P/E Ratio(TTM)
49.45
EPS(TTM)
28.41
P/B Ratio
6.93
Dividend Yield
0.00%
Industry P/E
37.32
Book Value
202.72
Debt to Equity
0.37
Face Value
10
Financial performance
JUN '26
₹183Cr
-5.10%
₹30.45Cr
-16.96%
050100150200
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
| Revenue growth | Value |
|---|---|
| 1Y (TTM) | +25% |
| 3Y CAGR | +206% |
| Profit growth | Value |
|---|---|
| 1Y (TTM) | +44% |
| 3Y CAGR | +289% |
About
Senores Pharmaceuticals Limited manufactures pharmaceutical formulations and active pharmaceutical ingredients (APIs).;
CEO/MD
Swapnil Jatinbhai Shah
Founded in
2017
NSE symbol
SENORES
Shareholding pattern
Mutual Funds Invested (4)
Similar stocks
| Stock | Mkt price (1D) | 52 week performance | Market cap | P/E ratio | P/B ratio | |
|---|---|---|---|---|---|---|
Caplin Point LaboratoriesCAPLIPOINT | ₹2,748.60 +156.00 (6.02%) | 20,886.87 | 30.81 | 6.2 | ||
PfizerPFIZER | ₹4,002.40 -12.40 (0.31%) | 18,304.58 | 24.9 | 4.36 | ||
Jubilant PharmovaJUBLPHARMA | ₹1,065.40 +53.30 (5.27%) | 16,999.70 | 48.37 | 2.4 | ||
Astrazeneca Pharma IndiaASTRAZEN | ₹6,751.50 +82.50 (1.24%) | 16,878.50 | 99.5 | 19.34 |
Livesquawk •
Senores Pharma plans INR130 crore CapEx in FY27 to expand oral solid capacity and pilot injectable plant.
Near-term run rate expected at INR60-75 crore for the next year, as per Concall update.
Livesquawk •
Senores Pharma projects 30-40% YoY growth in Branded Generics.
Strategic focus shifts to profitability with 35-40% EBITDA target.
Livesquawk •
Senores Pharma projects FY27 EBITDA margin at 18-20% despite Q1 dip to 14%.
Q1 FY27 margin fell from 20% in Q4 FY26; FY27 outlook remains strong.
2026
27
Jul
Quarterly Result
Release date
14
May
Annual Result
Release date
20
Jan
Quarterly Result
Release date
2025
6
Nov
Quarterly Result
Release date
23
Jul
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks